India’s first CAR T therapy NexCAR 19 shows promise as hospitals expand treatment nationwide

Published on 24 April 2026

It’s already live at 40 hospitals and gaining momentum

India’s first CAR T cell therapy, NexCAR 19, is delivering encouraging early results for a specific blood cancer. Now available at 40 hospitals, the indigenous developer ImmunoACT is scaling access and building confidence in homegrown advanced treatment. The big question: can this breakthrough meaningfully change outcomes in the fight against cancer’s toughest battles?

NexCAR 19 is India’s first CAR T therapy for a specific blood cancer
The therapy is now listed across 40 hospitals nationwide
ImmunoACT is expanding domestic capacity for advanced cancer care
Early signs raise hopes for better patient outcomes

#immunoact #cancer #healthcare #car t therapy #india

Read the full story at The Economic Times

This summarization was done by Beige for a story published on The Economic Times

India’s first CAR T therapy NexCAR 19 shows promise as hospitals expand treatment nationwide

The full experience is on mobile.